China Stroke Secondary Prevention Trial (CSSPT)
Primary Purpose
Stroke, Transient Ischemic Attack
Status
Withdrawn
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Folic Acid
Vitamin B6
Vitamin B12
placebo
placebo
placebo
Sponsored by
About this trial
This is an interventional prevention trial for Stroke focused on measuring folic acid, B vitamins, secondary prevention, stroke, randomized controlled trial, homocysteine
Eligibility Criteria
Inclusion Criteria:
- Patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or TIA
- Homocysteine level ≥ 15μmol/L
- Agree to take study medication;Be geographically accessible for follow-up
- Provide written informed consent
Exclusion Criteria:
- Other cause of ischemic stroke (cardioembolism; stroke of other determined etiology, and stroke of undetermined etiology according to TOAST subtypes) or hemorrhagic stroke (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding disorders etc)
- Use of vitamin supplements containing folate, B6 or B12
- Pregnancy or women of child-bearing potential who are at risk of pregnancy
- Limited life expectancy
Sites / Locations
- Xijing Hosptial
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
vitamin supplements
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Recurrent stroke
Myocardial infarction
Death due to other vascular causes
Secondary Outcome Measures
TIA
Revascularization procedures
Dementia
Depression
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01317849
Brief Title
China Stroke Secondary Prevention Trial
Acronym
CSSPT
Official Title
Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Withdrawn
Why Stopped
financial assistance financial assistance financial assistance financial assistance financial assistance without financial assistance
Study Start Date
July 2011 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
June 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xijing Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death.
Detailed Description
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke events and other combined incidence of recurrent vascular events and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within one months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blinded fashion to receive multi-vitamins or placebo. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the two years with a median follow-up of 3 years. Recruitment to the trial began in July 2011 and is planned to continue until December 2013. The investigators aim to complete final follow-up by the end of 2016.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Transient Ischemic Attack
Keywords
folic acid, B vitamins, secondary prevention, stroke, randomized controlled trial, homocysteine
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
vitamin supplements
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Folic Acid
Other Intervention Name(s)
folate
Intervention Description
0.8mg
Intervention Type
Drug
Intervention Name(s)
Vitamin B6
Other Intervention Name(s)
Pyridoxine
Intervention Description
10mg
Intervention Type
Drug
Intervention Name(s)
Vitamin B12
Other Intervention Name(s)
Cyanocobalamin
Intervention Description
500ug
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
0.8 mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
10mg
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
500ug
Primary Outcome Measure Information:
Title
Recurrent stroke
Time Frame
3 years
Title
Myocardial infarction
Time Frame
3 years
Title
Death due to other vascular causes
Time Frame
3 years
Secondary Outcome Measure Information:
Title
TIA
Time Frame
3 years
Title
Revascularization procedures
Time Frame
3 years
Title
Dementia
Time Frame
3 years
Title
Depression
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or TIA
Homocysteine level ≥ 15μmol/L
Agree to take study medication;Be geographically accessible for follow-up
Provide written informed consent
Exclusion Criteria:
Other cause of ischemic stroke (cardioembolism; stroke of other determined etiology, and stroke of undetermined etiology according to TOAST subtypes) or hemorrhagic stroke (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding disorders etc)
Use of vitamin supplements containing folate, B6 or B12
Pregnancy or women of child-bearing potential who are at risk of pregnancy
Limited life expectancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gang Zhao, MD
Organizational Affiliation
the Department of Neurology , Xijing Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Xijing Hosptial
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710032
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
23490255
Citation
Liu X, Shi M, Xia F, Han J, Liu Z, Wang B, Yang F, Li L, Wu S, Wang L, Liu N, Lv Y, Zhao G. The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke. Int J Stroke. 2015 Feb;10(2):264-8. doi: 10.1111/ijs.12017. Epub 2013 Mar 12.
Results Reference
background
Learn more about this trial
China Stroke Secondary Prevention Trial
We'll reach out to this number within 24 hrs